Antibodies against mac-1

Abstract

The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in signaling.

1 . An isolated monoclonal antibody or an antigen-binding portion thereof which
 a) binds to Mac-1,   b) specifically inhibits the interaction of CD40L with activated Mac-1 and   c) does not induce integrin outside-in signaling,   characterized in that the antibody or antigen-binding portion thereof comprises at least three CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8.   
     
     
         2 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof does not bind to non-activated Mac-1. 
     
     
         3 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof limits the expression of inflammatory cytokines. 
     
     
         4 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof blocks leukocyte recruitment in vitro and in vivo in intravital microscopy. 
     
     
         5 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof does not affect thrombotic and hemostatic functions of Mac-1. 
     
     
         6 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof binds specifically to a peptide having the sequence SEQ ID NO: 9 
     
     
         7 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof comprises at least four CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8. 
     
     
         8 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof comprises at least five CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8. 
     
     
         9 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof comprises six CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8. 
     
     
         10 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the light chain has an identity of at least 80% to the amino acid sequence of SEQ ID NO:1 and that the heavy chain has at least 80% identity to the amino acid sequence of SEQ ID NO:5. 
     
     
         11 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the light chain has the amino acid sequence of SEQ ID NO:1. 
     
     
         12 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the amino acid sequence of the heavy chain corresponds to SEQ ID NO:5. 
     
     
         13 . The antibody or antigen-binding portion thereof according to  claim 1  characterized in that the antibody or an antigen-binding portion thereof is selected from the group comprising F ab  fragments, single chain antibodies, diabodies and/or nanobodies. 
     
     
         14 . A pharmaceutical composition characterized in that it comprises a pharmaceutically active amount of an antibody or antigen-binding portion thereof according to  claim 1 . 
     
     
         15 . The pharmaceutical composition according to  claim 14  for the treatment of inflammation.